Cargando…
Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant
PURPOSE: Some transplant patients mount an insufficient response to standard COVID-19 vaccine (COVAX) dosing and a booster dose has now been approved. Vaccination carries the theoretical risk of stimulating antibody production to the donor. There are no prior studies surveying de novo donor specific...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988555/ http://dx.doi.org/10.1016/j.healun.2022.01.803 |
_version_ | 1784682986894000128 |
---|---|
author | Maybaum, S. Rahman, A. Malhame, K. Rossi, D. Wallach, F. Kon, Z. Stevens, G. |
author_facet | Maybaum, S. Rahman, A. Malhame, K. Rossi, D. Wallach, F. Kon, Z. Stevens, G. |
author_sort | Maybaum, S. |
collection | PubMed |
description | PURPOSE: Some transplant patients mount an insufficient response to standard COVID-19 vaccine (COVAX) dosing and a booster dose has now been approved. Vaccination carries the theoretical risk of stimulating antibody production to the donor. There are no prior studies surveying de novo donor specific HLA antibodies (dnDSA) after COVAX. HLA-DQ is the most common dnDSA post cardiac transplant and is associated with worse outcomes. We reviewed the development of dnDSA to HLA-DQ in cardiac transplant patients after COVAX. METHODS: DSA testing (luminex single antigen bead) was performed routinely at the time of surveillance endomyocardial biopsy. We retrospectively recorded any dnDSA to HLA-DQ with MFI >1000 after COVAX. We further identified a historical cohort (pre vaccination) of 32 patients who had DSA testing a minimum of 5 months after transplant. RESULTS: 32 adult patients completed COVAX (16 Pfizer-BioNTech, 8 Moderna, 8 Johnson and Johnson) 3-79 mths after transplantation. 16 patients had DSA testing 1-5 mths post COVAX (4-84 mths post transplant) (Table 1). Three patients (18.8 %) demonstrated dnDSA to HLA-DQ (MFI 6360-25,824) 10-20 weeks post COVAX and all had episodes of high grade acute cellular rejection. One additional patient had rejection post COVAX without dnDSA. All 3 patients with dnDSA had robust response to the vaccine with antibodies to spike protein RBD of > 200 U/ml (Elecsys®). Eight vaccinated patients without dnDSA had anti-RBD testing, half had titres > 200 U/ml. In the historical pre COVAX cohort, 3 patients (9 %) demonstrated dnDSA (2022-25480 MFI), one of these had cellular rejection and one developed antibody mediated rejection. CONCLUSION: One fifth of cardiac transplant recipients developed dnDSA in the weeks following COVAX, all associated with rejection. While no definitive conclusions may be drawn, we believe these data suggest the need for immunological surveillance after COVAX. This may be even more important after a booster dose. |
format | Online Article Text |
id | pubmed-8988555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89885552022-04-11 Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant Maybaum, S. Rahman, A. Malhame, K. Rossi, D. Wallach, F. Kon, Z. Stevens, G. J Heart Lung Transplant (782) PURPOSE: Some transplant patients mount an insufficient response to standard COVID-19 vaccine (COVAX) dosing and a booster dose has now been approved. Vaccination carries the theoretical risk of stimulating antibody production to the donor. There are no prior studies surveying de novo donor specific HLA antibodies (dnDSA) after COVAX. HLA-DQ is the most common dnDSA post cardiac transplant and is associated with worse outcomes. We reviewed the development of dnDSA to HLA-DQ in cardiac transplant patients after COVAX. METHODS: DSA testing (luminex single antigen bead) was performed routinely at the time of surveillance endomyocardial biopsy. We retrospectively recorded any dnDSA to HLA-DQ with MFI >1000 after COVAX. We further identified a historical cohort (pre vaccination) of 32 patients who had DSA testing a minimum of 5 months after transplant. RESULTS: 32 adult patients completed COVAX (16 Pfizer-BioNTech, 8 Moderna, 8 Johnson and Johnson) 3-79 mths after transplantation. 16 patients had DSA testing 1-5 mths post COVAX (4-84 mths post transplant) (Table 1). Three patients (18.8 %) demonstrated dnDSA to HLA-DQ (MFI 6360-25,824) 10-20 weeks post COVAX and all had episodes of high grade acute cellular rejection. One additional patient had rejection post COVAX without dnDSA. All 3 patients with dnDSA had robust response to the vaccine with antibodies to spike protein RBD of > 200 U/ml (Elecsys®). Eight vaccinated patients without dnDSA had anti-RBD testing, half had titres > 200 U/ml. In the historical pre COVAX cohort, 3 patients (9 %) demonstrated dnDSA (2022-25480 MFI), one of these had cellular rejection and one developed antibody mediated rejection. CONCLUSION: One fifth of cardiac transplant recipients developed dnDSA in the weeks following COVAX, all associated with rejection. While no definitive conclusions may be drawn, we believe these data suggest the need for immunological surveillance after COVAX. This may be even more important after a booster dose. Published by Elsevier Inc. 2022-04 2022-04-07 /pmc/articles/PMC8988555/ http://dx.doi.org/10.1016/j.healun.2022.01.803 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | (782) Maybaum, S. Rahman, A. Malhame, K. Rossi, D. Wallach, F. Kon, Z. Stevens, G. Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant |
title | Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant |
title_full | Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant |
title_fullStr | Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant |
title_full_unstemmed | Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant |
title_short | Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant |
title_sort | development of de novo donor specific antibodies following covid-19 vaccination in cardiac transplant |
topic | (782) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988555/ http://dx.doi.org/10.1016/j.healun.2022.01.803 |
work_keys_str_mv | AT maybaums developmentofdenovodonorspecificantibodiesfollowingcovid19vaccinationincardiactransplant AT rahmana developmentofdenovodonorspecificantibodiesfollowingcovid19vaccinationincardiactransplant AT malhamek developmentofdenovodonorspecificantibodiesfollowingcovid19vaccinationincardiactransplant AT rossid developmentofdenovodonorspecificantibodiesfollowingcovid19vaccinationincardiactransplant AT wallachf developmentofdenovodonorspecificantibodiesfollowingcovid19vaccinationincardiactransplant AT konz developmentofdenovodonorspecificantibodiesfollowingcovid19vaccinationincardiactransplant AT stevensg developmentofdenovodonorspecificantibodiesfollowingcovid19vaccinationincardiactransplant |